NCT00536263View on ClinicalTrials.gov

PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

PHASE3CompletedINTERVENTIONAL
Enrollment

671

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

November 30, 2009

Study Completion Date

November 30, 2009

Conditions
Hepatitis B, Chronic
Interventions
DRUG

pegylated interferon alpha-2b

1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks

DRUG

pegylated interferon alpha-2b

1.5 mcg/kg S.C. QW for 24 weeks

DRUG

pegylated interferon alpha-2b

1.5 mcg/kg S.C. QW for 48 weeks

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00536263 - PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327) | Biotech Hunter | Biotech Hunter